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Abstract
Background: The World Health Organization (WHO), like many other organisations around the world, has recognised
the need to use more rigorous processes to ensure that health care recommendations are informed by the best available
research evidence. This is the sixth of a series of 16 reviews that have been prepared as background for advice from the
WHO Advisory Committee on Health Research to WHO on how to achieve this.
Objectives: We reviewed the literature on determining which outcomes are important for the development of
guidelines.
Methods:  We searched five databases of methodological studies for existing systematic reviews and relevant
methodological research. We did not conduct a complete systematic review ourselves. Our conclusions are based on
the available evidence, consideration of what WHO and other organisations are doing and logical arguments.
Key questions and answers: We did not find a systematic review that addresses any of the following key questions
and we found limited relevant research evidence.
What methods should WHO use to identify important outcomes?
• Methods of outcome identification should be transparent and explicit.
• The consultation process should start with identification of all relevant outcomes associated with an intervention.
• Those affected, including consumers, should be involved in the selection of outcomes.
• A question driven approach (what is important?) is preferable to a data driven approach (what data are at hand?) to
identify important outcomes.
What type of outcomes should WHO consider and how should cultural diversity be taken account of in
the selection of outcomes?
• Desirable (benefits, less burden and savings) and undesirable effects should be considered in all guidelines.
• Undesirable effects include harms (including the possibility of unanticipated adverse effects), greater burden (e.g. having
to go to the doctor) and costs (including opportunity costs).
• Important outcomes (e.g. mortality, morbidity, quality of life) should be preferred over surrogate, indirect outcomes
(e.g. cholesterol levels, lung function) that may or may not correlate with patient important outcomes.
• Ethical considerations should be part of the evaluation of important outcomes (e.g. impacts on autonomy).
Published: 01 December 2006
Health Research Policy and Systems 2006, 4:18 doi:10.1186/1478-4505-4-18
Received: 07 April 2006
Accepted: 01 December 2006
This article is available from: http://www.health-policy-systems.com/content/4/1/18
© 2006 Schünemann et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Health Research Policy and Systems 2006, 4:18 http://www.health-policy-systems.com/content/4/1/18
Page 2 of 6
(page number not for citation purposes)
• If the importance of outcomes is likely to vary across cultures, stakeholders from diverse cultures should be consulted
and involved in the selection of outcomes.
How should the importance of outcomes be ranked?
• Outcomes should be ranked by relative importance, separated into benefits and downsides.
• Information from research on values and preferences should inform the ranking of outcomes whenever possible.
• If the importance of outcomes is likely to vary across cultures, ranking of outcomes should be done in specific settings.
• If evidence is lacking for an important outcome, this should be acknowledged, rather than ignoring the outcome.
Background
The World Health Organization (WHO), like many other
organisations around the world, has recognised the need
to use more rigorous processes to ensure that health care
recommendations are informed by the best available
research evidence. This is the sixth of a series of 16 reviews
that have been prepared as background for advice from
the WHO Advisory Committee on Health Research to
WHO on how to achieve this.
An outcome can be defined as a measure of an interven-
tion's desirable (benefits, less burden and savings) or
undesirable effects (including harms, greater burdens and
cost). Those making health care recommendations always
should consider the benefits, potential harms, including
the potential for unanticipated adverse effects, burdens
(e.g. having to take a pill), and costs, including opportu-
nity costs. Identifying all known and plausible outcomes
that are important to those affected and associated with
an intervention is a key step in formulating questions for
guideline development. Unfortunately, guideline devel-
opers sometimes select outcomes based on what has been
assessed in studies rather than based on what is important
to those affected.
Since interventions affect several outcomes (e.g. some
hypertensive treatments have effects on mortality, stroke,
diabetes, libido), guideline developers need to consider
their relative importance. This is also true for public
health and health systems interventions. For example,
media campaigns might cause anxiety as well as promot-
ing a desired health behaviour, and there are always asso-
ciated costs. At the very least, there are opportunity costs.
Patients may assign different values to outcomes than cli-
nicians and clinical experts involved in guideline develop-
ment [1]. In addition, surrogate outcomes such as
laboratory measures that are part of the clinician's reper-
toire often do not correlate with patient important out-
comes and guideline developers should scrutinize
surrogate outcomes about how directly they relate to
patient important outcomes.
In this paper we addressed the following questions:
￿ What methods should WHO use to identify important
outcomes?
￿ What type of outcomes should WHO consider and how
should cultural diversity be taken account of in the selec-
tion of outcomes?
￿ How should the importance of outcomes be ranked?
Questions related to integrating values and consumer
involvement are specifically addressed in another paper in
this series [2].
What WHO is doing now
The Guidelines for WHO Guidelines suggests the follow-
ing:
￿ "To identify the issues to be addressed, it is helpful to
develop a logic and analytical frameworks guide (Woolf,
1994)" [3]. (GWG 6C1 Process of developing guidelines)
￿ "Spell out any tradeoffs between the cost of applying
possible recommendations on a population basis, and the
population health impacts" in the second stage of guide-
line development. (section 5d Making recommendations)
￿ "All evidence, including that on safety, should be clearly
laid out in an evidence table" (GWG section 6C2).
Despite these guidelines, a review of several WHO guide-
lines (e.g., contraceptive use, hypertension, air pollution,
inpatient treatment of malnourished children, treatment
of non-breastfed children) revealed that the process of
outcome identification is usually not described.
What other organisations are doing
The UK National Institute for Health and Clinical Exce-
lence (NICE) defines a very explicit process for the identi-
fication of outcomes using the Population, Intervention,
Comparison and Outcome (PICO) format for the devel-Health Research Policy and Systems 2006, 4:18 http://www.health-policy-systems.com/content/4/1/18
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opment of questions [4]. The NICE handbook asks guide-
line panels to consider:
￿ What outcome is really important for the patient?
￿ Which outcomes should be considered: intermediate or
short-term measures (e.g., mortality, morbidity and treat-
ment complications, quality of life, cost, etc)?
Similarly, the National Health and Medical Research
Council of Australia bases its approach on the NICE hand-
book and defines the appropriateness of the outcomes by
asking "Are they relevant to the patient?" [5,6].
SIGN underlines (section 5.1. of the SIGN handbook for
guideline developers) that patients' perspectives should
be included early in the guideline development process
[7]. Therefore, SIGN prescribes to conduct a specific liter-
ature search designed to cover both quantitative and qual-
itative evidence about outcomes without limitations of
study design, but this is not (yet) done consistently
(Robin Habour, personal communication). In theory, the
results of this search inform the development of key ques-
tions. SIGN uses the PICO format for question develop-
ment.
The United States Preventive Services Taskforce (USPSTF)
[8] describes that value judgments are involved in using
the information in an outcomes table to rate either bene-
fits or harms. USPSTF uses a 4-point scale to rate impor-
tance. Value judgments are also needed to weigh benefits
against harms and to arrive at a rating of net benefit. The
USPSTF does not use formal processes for identifying out-
comes as part of the question formulation. Specialty soci-
eties do not consistently acknowledge a formal process for
question development and the processes are often not
transparent.
Methods
The methods used to prepare this review are described in
the introduction to this series [9]. Briefly, the key ques-
tions addressed in this paper were vetted amongst the
authors and the ACHR Subcommittee on the Use of
Research Evidence (SURE). We did not conduct a full sys-
tematic review. We reviewed existing guidelines for guide-
lines to identify processes for outcome identification and
ranking. We also searched PubMed using (guideline OR
policy making) and (identification) and (outcomes) as
search terms (MESH headings/keywords) for systematic
reviews and studies of methods for identifying outcomes
for guideline development (69 citations). We also
searched the Cochrane Methodology Register and Data-
base of Methodology Reviews using the keywords "out-
come" and "identification". We also searched databases
maintained by the Agency for Healthcare Research and
Quality (AHRQ, [10]) and the Guidelines International
Network (GIN, [11]). These searches were supplemented
with information obtained directly from guideline devel-
opment organizations and our own files. The answers to
the questions are our conclusions based on the available
evidence, consideration of what WHO and other organi-
sations are doing and logical arguments.
Findings
We did not find a systematic review that addresses any of
the key questions and we found very little relevant
research evidence.
What methods should WHO use to identify 
important outcomes?
Few guideline developers have included descriptions of
methods for the identification of important outcomes.
SIGN uses an approach that begins with conducting a
search for evidence using the patient perspective before
finalizing the formation of the question. Most other
guideline developers have not described formal processes
of identifying important outcomes when formulating
guideline questions. To be reproducible and understand-
able, the methods of outcome identification should be
transparent and explicit.
NICE suggests facilitating the process of formulating ques-
tions, "it may be helpful to construct a diagram listing
outcomes and other key criteria the [guideline] group has
considered important. Once the question has been
framed, key words can be identified as potential search
terms" [12]. NICE involves patient organistions in devel-
oping guideline scopes and routinely includes at least two
patient or caregiver members who provide a patient per-
spective on all guideline development activities including
the formulation of clinical questions and defining of rele-
vant outcomes [13]. Owens and Nease suggest the use of
influence diagrams to identify important outcomes and
focus guideline questions [14]. They argue this helps to
delineate an explicit link between interventions and out-
comes, shifts the focus from broad questions to more
sharply delineated questions to be addressed, and high-
light the importance of a clear, unambiguous statement of
whose benefit, downsides and costs are under considera-
tion. Thus, this limited evidence suggests that a consulta-
tion process should start with identification of all relevant
outcomes associated with an intervention.
Bravata and colleagues. conducted an overview of reviews
to identify innovative methods for question formulation
related to challenging topics in health care (organization,
delivery and financing of health care) [15]. They found
that the use of decision analytical frameworks for defining
a question and systematic methods such as influence dia-
grams influenced how questions were formulated. Fur-Health Research Policy and Systems 2006, 4:18 http://www.health-policy-systems.com/content/4/1/18
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thermore, systematic methods appeared to have an effect
on search strategies to identify underlying evidence.
There is little empirical evidence to inform decisions
about what methods to use to identify important out-
comes. Given the paucity of data on patients' and the pub-
lic's values WHO should consider using other evidence
such as systematic summaries and original research on
people's perspectives and experiences ("views" studies)
alongside trials of effectiveness. Summarizing views stud-
ies in a systematic way could lead to a greater breadth of
perspectives and a deeper understanding of public health
issues from the point of view of those targeted by inter-
ventions. Harden et al. suggest that this methodology is
likely to create greater opportunities for people's own per-
spectives and experiences to inform policies to promote
their health [16].
Compared to the limited evidence about methods to iden-
tify important outcomes in guidelines, there is a large lit-
erature that documents that the importance of outcomes
can vary within and across cultures, and between health
care professionals and patients [1,17]. In addition, both
clinical and public health interventions can have effects
that are important to consumers, but are not considered
important by researchers or health professionals in part
because values differ between decision makers. This sug-
gests two key elements of any approach that is used to
identify important outcomes. First, all relevant stakehold-
ers (including consumers) should be consulted at an early
stage in the process. Secondly, the formulation of ques-
tions and the search for evidence should then consider all
relevant outcomes.
What type of outcomes should WHO consider 
and how should cultural diversity be taken 
account of in the selection of outcomes?
The AGREE Collaboration states that the guidelines devel-
opment process "involves taking into account the bene-
fits, harms and costs of the recommendations, as well as
the practical issues attached to them" [18]. The AGREE
instrument suggests guidelines "should consider health
benefits, side effects, and risks of the recommendations.
For example, a guideline on the management of breast
cancer may include a discussion on the overall effects on
various final outcomes. These may include: survival, qual-
ity of life, adverse effects, and symptom management or a
discussion comparing one treatment option to another.
There should be evidence that these issues have been
addressed." It also suggests that the potential cost implica-
tions of applying the recommendations should have been
considered. In general, desirable and undesirable effects
should be considered in all guidelines. Undesirable effects
include harms (including the possibility of unanticipated
adverse effects), burdens (e.g. having to go to the doctor)
and costs (including opportunity costs).
The GRADE Working Group suggests that explicit judge-
ments should be made about which outcomes are critical,
which ones are important but not critical, and which ones
are unimportant and can be ignored. The group empha-
sizes that all important outcomes should be considered in
making a recommendation, but only critical ones should
be considered when making judgements about the overall
quality of the evidence underlying a recommendation
[19]. They recommend that it is important to consider
costs (resource utilisation) before making a recommenda-
tion. They also suggest that studies using surrogate out-
comes generally provide weaker evidence than those using
outcomes that are important, and these only should be
included when evidence for important outcomes is lack-
ing. Thus, important outcomes (e.g. mortality, morbidity,
quality of life) should be preferred over surrogate, indirect
outcomes (e.g. cholesterol levels, lung function) that may
or may not correlate with patient important outcomes.
Because the importance of different outcomes can vary
dramatically and the importance attached to different out-
comes may vary from culture to culture, it is important to
take cultural diversity into account when deciding which
outcomes are important [20-23]. Prenatal screening and
genetic counseling are examples of interventions for
which the importance of an outcome (abortion) varies
between individuals and across cultures, because of reli-
gious beliefs or values [24,25]. End of life decisions are
influenced by the roles of decision makers (clinician ver-
sus patient and family) and cultural differences [20,22].
The choice of using aspirin is related to the values and
preferences of diabetic patients and patients place very dif-
ferent values on preventing strokes than their health care
providers [1,26]. Cultural differences can be taken into
account through the involvement of stakeholders from
different cultures, and may require that judgments about
trade-offs between the benefits and downsides of an inter-
vention are specific for different cultures [27-29]. Values
of stakeholders should be elicited and transparently
described in recommendations. We offer strategies in
another article of this series [2].
Ethical considerations should also be taken into account
when selecting outcomes. For example, with directly
observed therapy for tuberculosis, individual rights to
refuse therapy (autonomy) may have to be sacrificed for
the benefit of society [30]. Explicit identification of ethical
consequences, and explicit judgments about trade-offs
such as these, can help to ensure that appropriate judg-
ments are made, help to resolve or clarify disagreements,
and facilitate local adaptation of guidelines.Health Research Policy and Systems 2006, 4:18 http://www.health-policy-systems.com/content/4/1/18
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How should the importance of outcomes be 
ranked?
Judgments about the balance between the benefits and
downsides of an intervention require judgments about
the relative importance of the different outcomes, either
explicitly or implicitly. Ranking outcomes by their relative
importance, separated into benefits and downsides in an
evidence profile [7,12] can help to focus attention on
those outcomes that are considered most important, and
help to resolve or clarify disagreements. Research on val-
ues and preferences should guide the ranking of out-
comes, whenever possible. Guideline panels may want to
search for research on the values associated with specific
outcomes of interest to inform judgments about their rel-
ative importance.
If the importance of outcomes varies across cultures, rank-
ing should be done by people in a specific setting, who
can pay due consideration to local values and preferences.
If evidence is lacking for an important outcome, this
should be acknowledged, rather than ignoring the out-
come.
Discussion
There is very limited evidence to inform decisions about
how to select and rank outcomes. However, we recom-
mend the use of systematic and transparent methods
involving key stakeholders, including consumers and peo-
ple from different cultures, to help ensure that all impor-
tant outcomes are considered and facilitate local
adaptation of guidelines. Limitations of our work include
the possibility that we have missed relevant studies.
Further work
Although it is possible that there is relevant empirical
research of which we are not aware, a complete systematic
review of the questions addressed in this paper is unlikely
to change the conclusion that there is very little research
evidence in this area. Evaluations comparing different
methods of identifying, selecting and ranking outcomes
are needed.
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